Announcements

    Drinks

      Updated analytical report on 4iG Nyrt.
      FRIDAY, 13/12/2024 - Scope Ratings GmbH
      Download PDF

      Updated analytical report on 4iG Nyrt.

      Following the recent affirmation of the BB- issuer rating with the revision of the Outlook to Stable from Positive, Scope has updated its analytical report on 4iG Nyrt.

      This monitoring note does not constitute a rating action, nor does it indicate the likelihood of a credit rating action in the short term.

      On 2 Dec 2024, Scope Ratings GmbH (Scope) has affirmed the BB- issuer rating on 4iG Nyrt. and revised the Outlook to Stable from Positive. Scope has also affirmed 4iG’s BB- senior unsecured debt rating. Click here for the corresponding rating action release.

      The latest information on the credit ratings in this monitoring note along with the associated rating history can be found on www.scoperatings.com.

      Click here to access the full report

      Related news

      Show all
      Scope affirms BBB-/Stable issuer rating of Germany’s investment holding Haniel

      17/4/2025 Rating announcement

      Scope affirms BBB-/Stable issuer rating of Germany’s ...

      Trade tensions, OPEC+ production hikes weigh down on oil & gas credit outlook

      17/4/2025 Research

      Trade tensions, OPEC+ production hikes weigh down on oil & ...

      Scope affirms B+ issuer rating on consumer goods company Naturtex and revises Outlook to Stable

      15/4/2025 Rating announcement

      Scope affirms B+ issuer rating on consumer goods company ...

      Scope proposes an update to its Chemicals Rating Methodology and invites comments

      14/4/2025 Research

      Scope proposes an update to its Chemicals Rating Methodology ...

      US tariff increases to have uneven direct cashflow, credit impact on European corporates

      11/4/2025 Research

      US tariff increases to have uneven direct cashflow, credit ...

      Scope proposes an update to its Pharmaceutical Companies’ Rating Methodology and invites comments

      4/4/2025 Research

      Scope proposes an update to its Pharmaceutical Companies’ ...